UK-based multinational GSK plc (LON: GSK) announced that it has received marketing approval from the US Food and Drug Administration (FDA) for its Penmenvy (meningococcal groups A, B, C, W, and Y vaccine) for use in individuals aged 10 through 25 years. The vaccine targets the five major serogroups of Neisseria meningitidis (A, B, C, W, and Y), which are commonly responsible for invasive meningococcal disease (IMD).
Vaccine Composition
Penmenvy combines the antigenic components of GSK’s two widely used meningococcal vaccines: Bexsero (meningococcal group B vaccine) and Menveo (meningococcal [groups A, C, Y, and W-135] oligosaccharide diphtheria CRM197 conjugate vaccine). This combination aims to provide broad protection against the most prevalent strains of meningococcal bacteria.
Clinical Studies
The approval was supported by positive results from two Phase III clinical studies. The safety data demonstrated that the vaccine’s safety profile is consistent with GSK’s licensed meningococcal vaccines, ensuring a reliable and effective treatment option for adolescents and young adults.-Fineline Info & Tech
Leave a Reply